Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling
Compose a Response to This Article
Other responses
No responses have been published for this article.
